Advancing global programmatic management of latent tuberculosis infection for at risk populations
Eur Respir J
.
2016 May;47(5):1327-30.
doi: 10.1183/13993003.00449-2016.
Authors
Haileyesus Getahun
1
,
Alberto Matteelli
2
,
Ibrahim Abubakar
3
,
Barbara Hauer
4
,
Emanuele Pontali
5
,
Giovanni Battista Migliori
6
Affiliations
1
Global TB Programme, World Health Organisation, Geneva, Switzerland
[email protected]
.
2
WHO Collaborating Centre for TB/HIV and TB Elimination, University of Brescia, Brescia, Italy.
3
MRC Clinical Trials Unit and Centre for Infectious Disease Epidemiology, UCL, London, UK.
4
Respiratory Infections Unit, Dept for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
5
Dept of Infectious Diseases Galliera Hospital, Genoa, Italy.
6
WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy.
PMID:
27132266
DOI:
10.1183/13993003.00449-2016
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antitubercular Agents*
Humans
Latent Tuberculosis*
Risk Factors
Tuberculosis
Substances
Antitubercular Agents